Postexposure prophylaxis after nonoccupational HIV exposure - Clinical, ethical, and policy considerations

被引:60
作者
Lurie, P
Miller, S
Hecht, F
Chesney, M
Lo, B
机构
[1] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Med, AIDS Program, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Ctr AIDS Res, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Div Gen Internal Med, Program Med Eth, San Francisco, CA 94143 USA
[5] Publ Citizens Hlth Res Grp, Washington, DC USA
[6] Univ Calif Berkeley, Sch Publ Hlth, Maternal & Child Hlth Program, Berkeley, CA 94720 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1998年 / 280卷 / 20期
关键词
D O I
10.1001/jama.280.20.1769
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the wake of recent breakthroughs in antiviral therapies and Centers far Disease Control and Prevention (CDC) recommendations advocating occupational postexposure prophylaxis (PEP), health care workers are increasingly receiving inquiries about PEP following exposures to the human immunodeficiency virus (HIV) through sex and injection drug use. The probability of HIV transmission by certain sexual or injection drug exposures is of the same order of magnitude as percutaneous occupational exposures for which the CDC recommends PEP. In such cases, if the exposure is sporadic, it seems appropriate to extrapolate from the data on occupational PEP and recommend prophylaxis. However, for individuals with continuing or low-risk exposures, we instead recommend referrals to state-of-the-art risk reduction programs. Clinicians, using local HIV seroprevalence data and their knowledge of transmission probabilities, can help exposed patients make an informed decision regarding PEP. Because of the large number of risky encounters that will not be treated prophylactically, even after significant outreach efforts, public health interventions that emphasize PEP as part of a comprehensive HIV prevention program should be confined to cities with highest HIV prevalences.
引用
收藏
页码:1769 / 1773
页数:5
相关论文
共 61 条
[1]  
[Anonymous], 1998, MMWR Recomm Rep, V47, P1
[2]  
[Anonymous], PREVENTING AIDS THEO
[3]   ETHINYL ESTRADIOL AND D-NORGESTREL IS AN EFFECTIVE EMERGENCY POSTCOITAL CONTRACEPTIVE - A REPORT OF ITS USE IN 1,200 PATIENTS IN A FAMILY-PLANNING CLINIC [J].
BAGSHAW, SN ;
EDWARDS, D ;
TUCKER, AK .
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 1988, 28 (02) :137-140
[4]   ZIDOVUDINE (AZT) REDUCES VIRUS TITER, RETARDS IMMUNE DYSFUNCTION, AND PROLONGS SURVIVAL IN THE LP-BM5 MURINE INDUCED IMMUNODEFICIENCY MODEL [J].
BASHAM, T ;
RIOS, CD ;
HOLDENER, T ;
MERIGAN, TC .
JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (05) :1006-1009
[5]  
BROWN WF, 1998, MAYORS SUMMIT AIDS H
[6]   TOWARDS AN UNDERSTANDING OF RISK BEHAVIOR - AN AIDS RISK REDUCTION MODEL (ARRM) [J].
CATANIA, JA ;
KEGELES, SM ;
COATES, TJ .
HEALTH EDUCATION QUARTERLY, 1990, 17 (01) :53-72
[7]  
*CDCP, 1998, MMWR-MORBID MORTAL W, V47, P151
[8]  
*CDCP, 1996, MMWR-MORBID MORTAL W, V45, P468
[9]  
*CDCP, 1995, NAT HIV SER SUMM UPD, V3
[10]  
*CDCP, 1995, MMWR-MORBID MORTAL W, V44, P929